Medrx corrects FY2024 financial results, revises cash flow statement
Medrx (TSE:4586) issued a correction to its previously released financial results summary for the fiscal year ending December 2024, citing errors in the preparation of the consolidated statement of changes in equity and the consolidated cash flow statement. The company stated that incorrect figures were used in the initial calculations of equity changes. Additionally, an error in calculating the cash flow statement prompted revisions to related figures. Consequently, the investment activities cash flow was adjusted to an outflow of ¥3 million. Finally, there was a correction to revenue recognition disclosures. The corrected financial statements reflecting these changes are now available. The effect was an overall increase of external sales to ¥257.915 million.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Medrx publishes news
Free account required • Unsubscribe anytime